vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.2M, roughly 1.4× Ares Commercial Real Estate Corp). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -29.2%, a 28.4% gap on every dollar of revenue. On growth, Ares Commercial Real Estate Corp posted the faster year-over-year revenue change (-24.5% vs -25.7%). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -15.9%).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
ACRE vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $18.7M |
| Net Profit | $-3.9M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | -29.2% | -6.9% |
| Net Margin | -29.2% | -0.8% |
| Revenue YoY | -24.5% | -25.7% |
| Net Profit YoY | 63.8% | 97.6% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $12.6M | $18.7M | ||
| Q1 25 | $14.9M | $50.9M | ||
| Q4 24 | $17.5M | $38.1M | ||
| Q3 24 | $16.7M | $33.4M | ||
| Q2 24 | $16.8M | $25.1M | ||
| Q1 24 | $18.7M | $41.5M |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $-11.0M | $-154.0K | ||
| Q1 25 | $9.3M | $23.5M | ||
| Q4 24 | $-10.7M | $18.9M | ||
| Q3 24 | $-5.9M | $5.7M | ||
| Q2 24 | $-6.1M | $-6.5M | ||
| Q1 24 | $-12.3M | $13.8M |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | -6.9% | ||
| Q1 25 | 64.4% | 44.4% | ||
| Q4 24 | -61.0% | 46.4% | ||
| Q3 24 | -35.3% | 12.3% | ||
| Q2 24 | -36.5% | -33.7% | ||
| Q1 24 | -65.9% | 28.1% |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | -0.8% | ||
| Q1 25 | 62.5% | 46.2% | ||
| Q4 24 | -60.9% | 49.6% | ||
| Q3 24 | -35.3% | 17.2% | ||
| Q2 24 | -36.5% | -26.0% | ||
| Q1 24 | -65.9% | 33.3% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $49.0M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $119.9M |
| Total Assets | $1.6B | $175.1M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | — | ||
| Q3 25 | $84.9M | — | ||
| Q2 25 | $90.0M | $49.0M | ||
| Q1 25 | $125.5M | $47.6M | ||
| Q4 24 | $63.8M | $38.1M | ||
| Q3 24 | $68.9M | $40.6M | ||
| Q2 24 | $70.6M | $43.2M | ||
| Q1 24 | $99.5M | $36.2M |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | — | ||
| Q3 25 | $521.0M | — | ||
| Q2 25 | $523.7M | $119.9M | ||
| Q1 25 | $542.1M | $25.0M | ||
| Q4 24 | $540.1M | $-456.0K | ||
| Q3 24 | $563.8M | $-23.5M | ||
| Q2 24 | $582.3M | $-31.2M | ||
| Q1 24 | $601.1M | $-31.7M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | $175.1M | ||
| Q1 25 | $1.5B | $98.5M | ||
| Q4 24 | $1.8B | $120.5M | ||
| Q3 24 | $1.9B | $139.0M | ||
| Q2 24 | $2.1B | $159.2M | ||
| Q1 24 | $2.1B | $184.7M |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | — | ||
| Q3 25 | $3.8M | — | ||
| Q2 25 | $4.9M | $-15.8M | ||
| Q1 25 | $8.0M | $-21.0M | ||
| Q4 24 | $35.5M | $-19.9M | ||
| Q3 24 | $8.4M | $-20.7M | ||
| Q2 24 | $8.7M | $-19.5M | ||
| Q1 24 | $11.4M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACRE
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
